Champions Oncology is known for its well-characterized TumorGraft® models which includes selected clinical data and a comprehensive profile of molecular data from Whole Exome Sequencing and RNA sequencing analyses. As a result we are able to freely provide both raw and processed (human-only reads) data on mutation status, gene fusion events, copy number variations and mRNA expression levels. This ensures confidence that you are selecting relevant models to run on study and can assess response data in relation to genomic profiling We have also tested these models for sensitivity to many different reference compounds and standards of care.
The power of working with Champions Oncology is that you gain access to not only our TumorGraft® database and associated model characterization data, but you also gain access to our expert team of bioinformatic scientists whom work to evaluate the data from your studies and look for key insights such as biomarkers of response/resistance that can be used to stratify clinical trial design and illustrate those insights in a publication-worthy manner.
Principal Component Analysis (PCA) for gene expression across 18,000 genes demonstrating the close association of prostate PDX models developed from the same patient at different treatment stages (blue and red text) compared to unmatched prostate models (black text).
Comparable allele frequencies identified between mutations found in four PDX models and matched patient tumor samples.
Mutation lollipop diagram highlighting spectrum of mutations identified in ERBB2 across Champions PDX models.
Unsupervised hierarchical clustering of models based on a gene signature for PARP inhibitor response or resistance (Peng, G et al, Nat. Comm., 2014), highlighting potential responders and non-responders to PARP inhibition.